Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary

被引:34
作者
Argiris, A
Smith, SM
Stenson, K
Mittal, BB
Pelzer, HJ
Kies, MS
Haraf, DJ
Vokes, EE
机构
[1] Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[3] Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA
关键词
chemotherapy; head and neck cancer; occult primary; radiotherapy; squamous cell carcinoma;
D O I
10.1093/annonc/mdg330
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Our aim was to explore the use of concurrent chemoradiotherapy in the management of patients with squamous cell carcinoma of the head and neck from an occult primary (HNCOP). Patients and methods: From 1991 to 2000, 25 patients with T0N2M0 or T0N3M0 HNCOP were entered into five sequential phase II clinical trials. Chemoradiotherapy consisted of a split course of radiotherapy with concurrent 5-fluorouracil and hydroxyurea either alone or with cisplatin, or paclitaxel. Two of the five protocols incorporated induction chemotherapy. Results: Nodal stage was N2a in five patients (20%), N2b in 13 (52%), N2c in one (4%) and N3 in six (24%). Twenty-two patients (88%) underwent neck dissection; 14 of 22 patients underwent neck dissection before initiating protocol therapy. Total radiation doses of 55-75 Gy (median 60 Gy) were delivered; radiation fields included the potential sites of mucosal primaries and the neck bilaterally. Selected patients received a radiation boost to the involved neck. With a median follow-up of 3.9 years, three patients have progressed (one local, two distant) and seven patients have died. Deaths were due to disease progression (three) or unrelated causes (four), No metachronous primaries developed. The 5-year progression-free and overall survival was 87% and 75%, respectively. Conclusion: Combined-modality treatment with intensive chemoradiotherapy results in excellent disease control and long-term survival for patients with N2-N3 HNCOP and compares favorably with traditional therapy.
引用
收藏
页码:1306 / 1311
页数:6
相关论文
共 29 条
[1]   Update on chemoradiotherapy for head and neck cancer [J].
Argiris, A .
CURRENT OPINION IN ONCOLOGY, 2002, 14 (03) :323-329
[2]  
ARGIRIS A, 2002, P AN M AM SOC CLIN, V21, pA910
[3]  
BROCKSTEIN BE, 2002, P AN M AM SOC CLIN, V21, pA918
[4]  
Colletier PJ, 1998, HEAD NECK-J SCI SPEC, V20, P674, DOI 10.1002/(SICI)1097-0347(199812)20:8<674::AID-HED3>3.0.CO
[5]  
2-H
[6]  
Cooper J. S., 2002, International Journal of Radiation Oncology Biology Physics, V54, P2, DOI 10.1016/S0360-3016(02)03058-4
[7]  
DEBRAUD F, 1989, CANCER, V64, P510, DOI 10.1002/1097-0142(19890715)64:2<510::AID-CNCR2820640225>3.0.CO
[8]  
2-2
[9]  
Friesland S, 2001, ACTA ONCOL, V40, P24
[10]  
FU KK, 1994, FRONT RADIAT THER ON, V28, P66